false
0001500198
0001500198
2024-08-14
2024-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 14, 2024
NeuroOne Medical Technologies Corporation
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40439 |
|
27-0863354 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
7599 Anagram Dr., Eden Prairie, MN 55344
(Address of principal executive offices and zip
code)
952-426-1383
(Registrant’s telephone number including
area code)
(Registrant’s former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
NMTC |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 14, 2024, NeuroOne Medical Technologies
Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30,
2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. of
Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that
section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended,
or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as
expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NEUROONE MEDICAL TECHNOLOGIES CORPORATION |
Dated: August 14, 2024 |
|
|
|
By: |
/s/ David Rosa |
|
|
David Rosa |
|
|
Chief Executive Officer |
2
Exhibit 99.1
NeuroOne® Reports Third Quarter Fiscal
Year 2024 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., August 14, 2024 (GlobeNewswire) -- NeuroOne Medical
Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on
improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results
for the third quarter fiscal year 2024 ended June 30, 2024.
Third Quarter Fiscal Year 2024 and Recent Business Updates
Financial Highlights:
| ● | Product revenue of $826,000 in Q3 2024, compared to $630,000 in Q3 2023 |
| ● | Reduced operating expenses from $3.8 million in Q3 2023 to $3.1 million in
Q3 2024 |
| ● | Raised an additional $1.6 million using the ATM Program in Q3 2024 |
| ● | Completed $2.65 million private placement and entered into $3.0 million secured
credit facility agreement in August 2024 |
Evo® sEEG:
| ● | Completed manufacturing transition from sEEG diagnostic electrodes to OneRF
electrodes |
OneRF™ Ablation System:
| ● | Continued limited commercial launch of the OneRF™ Ablation System,
including first shipments, implants and ablations with OneRF™ Ablation System |
| ● | Completed OneRF™ Ablation System training for four sites and initiated
sales quote process with 12 additional sites |
| ● | Implanted ~200 RF electrodes and performed more than 50 RF ablations on 3
patients |
| ● | Signed a non-binding term sheet with an undisclosed global medical technology
company to distribute our OneRF™ Ablation System. The term sheet is non-binding, and the partnership is subject to the negotiation
and execution of definitive documentation, due diligence, and other customary closing conditions |
| ● | Exhibited the OneRF™ Ablation System at the Association of Neurological
Surgeons (AANS) Annual Scientific Meeting in May and the American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
in June |
| ● | The Centers for Medicare and Medicaid Services (CMS) approved and granted
a new ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) code for the OneRF™ ablation
procedure. The new code will be effective October 1, 2024 and allows hospital reporting of inpatient procedures that are performed using
the OneRF™ Ablation System ensuring efficient and accurate documentation, billing, and analysis |
| ● | Presented posters on preclinical evaluation and ex vivo lesion characterization
of OneRF™ Ablation System at the AANS Annual Scientific Meeting in May |
sEEG-Based Drug Delivery Program:
| ● | Completed feasibility testing in vivo study providing histology data |
| ● | Completed drug compatibility and adsorption testing |
| ● | Presented posters on feasibility bench testing and in vivo studies of sEEG-based
drug delivery into the brain at the American Association of Pharmaceutical Scientists (AAPS-NBC) and the American Society of Gene &
Cell Therapy (ASGCT) in May |
| ● | Continued discussions with potential targeted strategic partners for use
in clinical studies and research |
Spinal Cord Stimulation (SCS) Percutaneous Paddle Lead Program:
| ● | Successfully completed acute animal study in large animal model to evaluate
stimulation performance of our percutaneous paddle lead for back and neck pain |
| ● | Successfully completed cadaver lab with physician key opinion leaders to
further advance the development of a percutaneous implantation technique for our thin-film SCS percutaneous paddle electrodes |
| ● | Finalized NeuroOne paddle lead design, including testing of electrode specifications |
| ● | Filed a provisional patent on a connector that is compatible with our thin-film
SCS electrodes |
Dave Rosa, CEO of NeuroOne, commented, “We accomplished several
key milestones this quarter. We are most excited about completing the first RF ablation cases with our first-to-market OneRF™ Ablation
System. We also signed a non-binding term sheet with a large strategic partner to serve as our distribution partner and accelerate the
launch of the OneRF™ Ablation System. In August, we completed a financing, entered into a credit facility agreement, and are making
good progress with our product pipeline, including additional RF ablation applications, sEEG-based drug delivery and a percutaneous paddle
lead for spinal cord stimulation. We are looking forward to securing additional strategic partners for these exciting programs leveraging
our thin-film electrode platform technology.”
Key Upcoming Milestones
OneRF™ Ablation System:
| ● | Finalize strategic partnership for distribution of OneRF™ Ablation
System |
| ● | Continue to add new centers for our limited commercial launch |
| ● | Exhibit OneRF™ Ablation System at the 2024 World Congress of Stereotactic
and Functional Neurosurgery meeting in September |
| ● | Present posters on OneRF™ Ablation System at the Congress of Neurological
Surgeons 2024 annual meeting in September |
| ● | Continue to explore additional ablation applications and strategic partnership
opportunities in other attractive markets that could benefit from NeuroOne’s high-resolution, thin-film electrode technology and
RF generator |
Spinal Cord Stimulation Percutaneous Paddle Lead Program:
| ● | Initiate discussions with potential strategic partners to license or acquire
the NeuroOne Spinal Cord Stimulation percutaneous paddle lead product |
Third Quarter Fiscal Year 2024 Financial
Results
Product revenue was $826,000 in the third quarter of fiscal 2024, compared
to product revenue of $630,000 in the third quarter of fiscal 2023. For the first nine months of fiscal 2024, product revenue was $3.2
million, compared to $1.2 million for the same period in fiscal 2023. The Company had no collaboration revenue in the first nine months
of fiscal 2024, compared to collaboration revenue of $1.46 million in the first nine months of fiscal 2023. Collaboration revenue in 2023
was derived from the Zimmer Development Agreement and represents the portion of the exclusivity and milestone fee payments eligible for
revenue recognition during the period.
Total operating expenses in the third quarter of fiscal 2024 were $3.1
million, compared with $3.8 million in the same period of the prior fiscal year. Research and Development (R&D) expense in the third
quarter of fiscal 2024 was $1.2 million compared with $1.9 million in the third quarter of fiscal 2023. Selling, General and Administrative
(SG&A) expenses were $1.9 million during each of the three months ended June 30, 2024 and 2023. For the first nine months of fiscal
2024, total operating expenses were $10.0 million, compared with $10.5 million in the same period of fiscal 2023. R&D expense in the
first nine months of fiscal 2024 was $4.0 million compared with $5.2 million in the same period of fiscal 2023. SG&A expense in the
first nine months of fiscal 2024 was $6.1 million compared with $5.3 million in the prior year period.
Net loss was $2.8 million for the third quarter of fiscal 2024, compared
to a net loss of $3.5 million in the third quarter of fiscal 2023. Net loss for the first nine months of fiscal 2024 was $9.0 million
compared with $8.7 million in the same period of fiscal 2023.
In the third quarter of fiscal 2024, the Company sold common stock
under the ATM Program at an average price of $1.19 per share, from which the Company received net proceeds of $1.6 million.
As of June 30, 2024, the Company had cash and cash equivalents of $1.6
million, compared to $5.3 million as of September 30, 2023. The Company had working capital of $2.2 million as of June 30, 2024, compared
to working capital of $5.5 million as of September 30, 2023.
The Company had no debt outstanding as of June 30, 2024.
On August 2, 2024, the Company completed a $2.65 million private placement,
resulting in $2.55 million in net proceeds, and entered into a $3.0 million secured credit facility agreement. The Company has not borrowed
anything under the credit facility agreement at this time.
Conference Call and Webcast
Wednesday, August 14, 2024, at 4:30 PM Eastern Time
Participants:
Toll Free: 877-545-0320
International: 973-528-0002
Participant Access Code: 579769
Phone Replay:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 51065
Available through August 28, 2024
Live Webcast:
Join here.
Webcast replay available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage
company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions
for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries
and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications
for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information,
visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that
reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed
or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases
“may,” “might,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,”
“predict,” “project,” “potential,” “target,” “seek,” “contemplate,”
“continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other
comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding
securing a strategic partnership for distribution of the OneRF™ Ablation System, the addition of new centers for the Company’s
limited commercial launch of the OneRF™ Ablation System, potential strategic partnership opportunities, continued development of
the Company’s electrode technology program (including our drug delivery program and spinal cord stimulation program), business strategy,
market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although
NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on
a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual
future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic
partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions,
labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical
trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives
and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our
technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements
or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for
our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable
to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the
heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements
speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements
for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order
of a physician.
Contact:
800-631-4030
ir@nmtc1.com
NeuroOne Medical Technologies Corporation
Condensed Balance Sheets
| |
As of June 30, | | |
As of September 30, | |
| |
2024 | | |
2023 | |
| |
(unaudited) | | |
| |
Assets | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 1,619,977 | | |
$ | 5,322,493 | |
Accounts receivable | |
| 410,551 | | |
| — | |
Inventory | |
| 1,793,432 | | |
| 1,726,686 | |
Prepaid expenses | |
| 261,477 | | |
| 263,746 | |
Total current assets | |
| 4,085,437 | | |
| 7,312,925 | |
Intangible assets, net | |
| 72,841 | | |
| 89,577 | |
Right-of-use assets | |
| 281,833 | | |
| 169,059 | |
Property and equipment, net | |
| 472,486 | | |
| 525,753 | |
Total assets | |
$ | 4,912,597 | | |
$ | 8,097,314 | |
| |
| | | |
| | |
Liabilities and Stockholders’ Equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 759,260 | | |
$ | 685,104 | |
Accrued expenses and other liabilities | |
| 931,700 | | |
| 1,107,522 | |
Total current liabilities | |
| 1,690,960 | | |
| 1,792,626 | |
Operating lease liability, long term | |
| 209,910 | | |
| 55,284 | |
Total liabilities | |
| 1,900,870 | | |
| 1,847,910 | |
| |
| | | |
| | |
Commitments and contingencies (Note 4) | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding. | |
| — | | |
| — | |
Common stock, $0.001 par value; 100,000,000 shares authorized; 27,846,722 and 23,928,945 shares issued and outstanding as of June 30, 2024 and September 30, 2023, respectively. | |
| 27,847 | | |
| 23,929 | |
Additional paid–in capital | |
| 74,637,698 | | |
| 68,911,778 | |
Accumulated deficit | |
| (71,653,818 | ) | |
| (62,686,303 | ) |
Total stockholders’ equity | |
| 3,011,727 | | |
| 6,249,404 | |
Total liabilities and stockholders’ equity | |
$ | 4,912,597 | | |
$ | 8,097,314 | |
NeuroOne Medical Technologies Corporation
Condensed Statements of Operations
(unaudited)
| |
For the Three Months Ended | | |
For the Nine Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Product revenue | |
$ | 825,776 | | |
$ | 629,906 | | |
$ | 3,180,719 | | |
$ | 1,210,661 | |
Cost of product revenue | |
| 543,904 | | |
| 386,240 | | |
| 2,242,114 | | |
| 947,799 | |
Product gross profit | |
| 281,872 | | |
| 243,666 | | |
| 938,605 | | |
| 262,862 | |
| |
| | | |
| | | |
| | | |
| | |
Collaborations revenue | |
| — | | |
| — | | |
| — | | |
| 1,455,188 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Selling, general and administrative | |
| 1,881,099 | | |
| 1,862,389 | | |
| 6,057,520 | | |
| 5,347,234 | |
Research and development | |
| 1,194,674 | | |
| 1,891,512 | | |
| 3,951,559 | | |
| 5,161,322 | |
Total operating expenses | |
| 3,075,773 | | |
| 3,753,901 | | |
| 10,009,079 | | |
| 10,508,556 | |
Loss from operations | |
| (2,793,901 | ) | |
| (3,510,235 | ) | |
| (9,070,474 | ) | |
| (8,790,506 | ) |
Other income, net | |
| 26,376 | | |
| 41,462 | | |
| 102,959 | | |
| 66,136 | |
Loss before income taxes | |
| (2,767,525 | ) | |
| (3,468,773 | ) | |
| (8,967,515 | ) | |
| (8,724,370 | ) |
Provision for income taxes | |
| — | | |
| — | | |
| — | | |
| — | |
Net loss | |
$ | (2,767,525 | ) | |
$ | (3,468,773 | ) | |
$ | (8,967,515 | ) | |
$ | (8,724,370 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share: | |
| | | |
| | | |
| | | |
| | |
Basic and diluted | |
$ | (0.10 | ) | |
$ | (0.20 | ) | |
$ | (0.35 | ) | |
$ | (0.52 | ) |
Number of shares used in per share calculations: | |
| | | |
| | | |
| | | |
| | |
Basic and diluted | |
| 27,352,660 | | |
| 17,578,871 | | |
| 25,746,503 | | |
| 16,740,546 | |
6
v3.24.2.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024